<< Findings could lead to new neurological treatments | FDA grants orphan drug status to Advanced Life Sciences' Restanza >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | العربية | Nederlands | Filipino | Ελληνικά | हिन्दी | Bahasa | Русский | Svenska | Polski

Mobetron portable radiation therapy system for breast cancer treatment

Published on September 16, 2009 at 12:53 AM · No Comments

One minute of radiation in the operating room (OR) could save the lives of thousands of women being treated for breast cancer in the US today. According to a growing body of research, a 60-second course of radiation therapy delivered during surgery dramatically improves results. But, until recently, logistical and administrative difficulties prevented most patients from receiving this crucial treatment until weeks after their procedures.

Now, a portable, self-contained radiation therapy system, the Mobetron from IntraOp Medical Corporation (OTCBB: IOPM; Sunnyvale, Calif.), is changing all that. St. Joseph Hospital (Orange, Calif.), one of only 16 prestigious designated National Cancer Institute Community Cancer Centers, this month introduced the first ongoing intraoperative electron radiation therapy (IOERT) program for breast cancer. During lumpectomy surgery, St. Joseph’s patients receive a high dose of therapy focused specifically on the tumor site, known as a “boost.” Given the benefits, other facilities are expected to follow suit.

Felix Sedlmayer, MD, one of the world’s leading IOERT researchers and the principal investigator of IOERT boost trials conducted by six European medical centers over the past decade, concluded that IOERT cut breast cancer five year recurrence rates dramatically, from an average of 5% to less than 1%.

“If the IOERT boost were a standard technique in the US, every year, more than 5000 breast cancer recurrences could have be avoided,” according to Roland Reitsamer, MD, a surgeon at the University of Salzburg, where the technique has been studied extensively for the past decade. Each one of those recurrences typically would result in a subsequent mastectomy, which also would be avoided. A prestigious Lancet review of studies on breast cancer found a 25% increase in 15 year survival for patients with no recurrences at five years, suggesting that IOERT boost could have a significant impact on the survival of thousands of women worldwide.

What every woman should know about intraoperative radiation

It seems a matter of common sense. Lumpectomy is typically followed by a six-week course of radiation therapy to help eliminate any remaining malignant cells. Treatment takes place at least four weeks after surgery when the breast has healed. Because traditional, post-operative radiation is delivered externally, it must pass through the body to reach diseased areas, and healthy tissue may be damaged in the process. Additionally, once surgery is complete, physicians no longer have direct access to the target area to easily and precisely deliver radiation.

So why not begin the radiation treatment during the surgery itself? This would immediately target any remaining cancer cells, while allowing complete access to the tumor area for greater precision in radiation delivery. It also would spare radiation dose to surrounding tissue and reduce the number of days a woman has to travel to a cancer center for external treatment after surgery. In fact, at St. Joseph, IOERT will shorten the course of post-operative radiation by seven to 10 days by delivering the targeted boost dose prior to, rather than after, traditional treatments.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading